Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial

Authors

  • K. A. Skorupski,

    Corresponding author
    1. Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, CA, USA
    • Correspondence address:

      K. A. Skorupski

      Veterinary Medicine: Surgical and Radiological Sciences

      Room 2112, Tupper Hall

      University of California

      1 Shields Avenue

      Davis, CA 95616, USA

      e-mail: kskorups@ucdavis.edu

    Search for more papers by this author
  • J. M. Uhl,

    1. Veterinary Medical Teaching Hospital, University of California, Davis, CA, USA
    Search for more papers by this author
    • Present address: College of Veterinary Medicine, University of Minnesota, St. Paul, MN, USA
  • A. Szivek,

    1. Veterinary Medical Teaching Hospital, University of California, Davis, CA, USA
    Search for more papers by this author
    • Present address: Veterinary Specialty Center of Tucson, Tucson, AZ, USA
  • S. D. Allstadt Frazier,

    1. Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, CA, USA
    Search for more papers by this author
    • Present address: Department of Small Animal Clinical Sciences, University of Tennessee, Knoxville, TN, USA
  • R. B. Rebhun,

    1. Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, CA, USA
    Search for more papers by this author
  • C. O. Rodriguez Jr.

    1. Department of Veterinary Surgical and Radiological Sciences, University of California, Davis, CA, USA
    Search for more papers by this author

  • This research was presented, in part, at the 2009 annual meeting of the Veterinary Cancer Society in Austin, TX, USA.

Abstract

Despite numerous published studies describing adjuvant chemotherapy for canine appendicular osteosarcoma, there is no consensus as to the optimal chemotherapy protocol. The purpose of this study was to determine whether either of two protocols would be associated with longer disease-free interval (DFI) in dogs with appendicular osteosarcoma following amputation. Dogs with histologically confirmed appendicular osteosarcoma that were free of gross metastases and underwent amputation were eligible for enrollment. Dogs were randomized to receive either six doses of carboplatin or three doses each of carboplatin and doxorubicin on an alternating schedule. Fifty dogs were included. Dogs receiving carboplatin alone had a significantly longer DFI (425 versus 135 days) than dogs receiving alternating carboplatin and doxorubicin (P = 0.04). Toxicity was similar between groups. These results suggest that six doses of carboplatin may be associated superior DFI when compared to six total doses of carboplatin and doxorubicin.

Ancillary